US Corporate Board Director Changes SEC Filings — November 02, 2026

USA Board Room Changes

By Gunpowder Editorial ·

39 high priority 39 total filings analysed

Executive Summary

The 39 filings reveal a broad wave of C-suite and board turnover, with 20+ officer changes and 12 board changes announced, many effective in late 2026 or early 2027. Succession activity is concentrated in CFO roles (Keysight, Upwork, Ur-Energy, Syndax, Lindsay, PG&E, CSB, Coronado, TE Connectivity) and CEO transitions (Telos, CVG, Fluence, FHLB Chicago, Apogee, Lennox segment).

A subset of filings also included Q3 2026 results, showing a stark divergence: Hinge Health posted record revenue (+52% YoY) and a swing to GAAP profitability, while Upwork’s marketplace revenue fell 9% YoY and GSV declined 10.1%, and Syndax reported an 82% revenue jump but a Phase 2 trial failure. Board changes were mostly routine, but Anavex Life Sciences saw three directors resign citing strategic misalignment, a negative signal. Insider activity was not disclosed in these 8-Ks, but severance and retention arrangements (Advantage Solutions, Elme Communities, Apogee) suggest defensive positioning. Overall, the filings point to a market rewarding operational execution and margin expansion, while penalizing structural declines and strategic discord.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from October 30, 2026.

Investment Signals (12)

  • ▲

    Q3 2026 revenue $235.0M (+52% YoY), GAAP operating margin 21% vs -4% prior year, FCF $112.7M (48% margin); FY2026 revenue guidance raised to $880M midpoint (+50% YoY) and non-GAAP operating margin to 30% midpoint (~1,000 bps improvement)

  • Q3 2026 total revenue $83.3M (+82% YoY), driven by Revuforj +90% and Niktimvo +47%; net loss narrowed to $49.4M from $60.7M despite R&D increase; CFO transition to Aaron Ondrey effective Nov 9

  • Q3 2026 revenue $208.1M (+36.5% YoY), gross margin expanded 300 bps to 13.5%, GAAP net income $5.6M vs -$6.8M; adjusted operating margin improved to 2.7% from 1.0%; FY revenue outlook raised to $755-$775M

  • Cash runway extended into 2029; 2026 cash opex guidance reiterated <$375M, 2027 <$360M; REC-4881 Phase 2 data positive (87% patients reduced polyp burden); Sanofi milestone $10M triggered; Fred Hassan appointed Board Chair

  • Planned CFO succession with 13-year CFO Neil Dougherty transitioning to advisory role through FY2027; no change to Q4 FY2026 outlook, demand strong; Q4 results Nov 19

  • CEO succession from John Wood (since 1994) to Mark Griffin effective Nov 2; continuity signaled, Q3 results Nov 9

  • ▲

    Appointed former EY U.S. CEO Julie Boland to board, expanding to 11 directors (10 independent); adds financial and governance expertise

  • ▲

    Appointed Menassie Taddese (ex-Viatris Emerging Markets President, ~$3B business) to board and Audit Committee; brings global commercial and financial expertise

  • Q3 2026 revenue $185.6M with GAAP net income $31.8M (+8% YoY) and adjusted EBITDA margin 34.4%, but GSV declined 10.1% YoY and active clients fell 10%; CFO transition to Peter Sanborn [NEUTRAL/BEARISH]

  • Three directors resigned citing strategic misalignment, including Audit Committee Chair; negative governance signal

  • Terminating retention agreements and dissolving on Nov 6; delisted from NYSE, now OTC; cash payouts to officers

  • Extended CEO Donald Nolan’s term through April 30, 2027, with $250K transition bonus and $1.75M annualized RSU grants while searching for permanent CEO; leadership continuity but transition risk

Risk Flags (10)

  • ▼

    Three directors resigned effective Oct 28 citing views on strategic direction not aligned with Board and management; Audit Committee Chair and member departed, forcing committee reconstitution; potential governance and strategy instability

  • Upwork↓ [HIGH RISK]
    ▼

    GSV declined 10.1% YoY to $914.1M, marketplace revenue fell 9% to $159.3M, active clients dropped 10% to 717K, and free cash flow fell 22% to $53.9M; gross margin compressed 115 bps YoY; nine-month net income fell 11% and FCF fell 38%

  • ▼

    MAXPIRe Phase 2 trial of axatilimab in IPF failed primary endpoint; development discontinued; despite revenue growth, pipeline setback increases reliance on Revuforj and Niktimvo

  • Blink Charging↓ [MEDIUM RISK]
    ▼

    8-K discloses officer change and bylaws amendment but identity, role, and reason not disclosed; potential leadership instability at small-cap EV charging company

  • Fluence Energy↓ [MEDIUM RISK]
    ▼

    Appointed interim CEO Axel Meier at $1.015M salary; explicitly excluded from Executive Severance Plan; discretionary bonus tied to placing permanent CEO; interim status creates uncertainty

  • Apogee Enterprises↓ [MEDIUM RISK]
    ▼

    CEO role remains in transition; Nolan extended through April 2027 with $250K transition bonus and $1.75M annualized RSUs; no permanent successor named

  • CEO Michael Ericson to conclude tenure Dec 31, 2026; interim CEO Virxhini Gjonzeneli appointed while search for permanent CEO; leadership transition at government-sponsored enterprise

  • ▼

    Deprioritized REC-617 and REC-3565 to pursue partnerships; registrational REC-4881 trial not expected until H2 2027; REC-1245 expansion data also H2 2027; pipeline delays

  • Elme Communities↓ [MEDIUM RISK]
    ▼

    Dissolving Nov 6; delisted from NYSE; retention agreements terminated with cash payouts; liquidation process may limit upside

  • Greenlane Holdings↓ [MEDIUM RISK]
    ▼

    Appointed Peter Kampian to board; company reiterates digital asset treasury strategy focused on BERA token; crypto exposure adds volatility

Opportunities (10)

  • Hinge Health↓ (OPPORTUNITY)
    ◆

    Raised FY2026 revenue guidance to $880M midpoint (+50% YoY) and non-GAAP operating margin to 30% midpoint; Q3 GAAP profitability swing; potential continued outperformance

  • ◆

    Raised FY revenue outlook to $755-$775M; margin expansion and return to profitability; new CEO David Ruppel effective Nov 9 could drive further operational improvements

  • ◆

    Positive Phase 2 data for REC-4881 and REC-1245; cash runway into 2029; Sanofi milestone; potential partnership deals for deprioritized assets; registrational trial H2 2027 catalyst

  • ◆

    Strong revenue growth (+82% YoY) and narrowed net loss; new CFO Aaron Ondrey effective Nov 9; investors may focus on commercial execution despite IPF setback

  • Keysight Technologies↓ (OPPORTUNITY)
    ◆

    CFO succession with experienced internal candidate Jason Kary; demand strong across end markets; Q4 results Nov 19 could provide positive catalyst

  • Telos Corporation↓ (OPPORTUNITY)
    ◆

    New CEO Mark Griffin (35-year tenure) could accelerate turnaround; Q3 results Nov 9; Wood remains Chairman focusing on product roadmap

  • Deere & Co↓ (OPPORTUNITY)
    ◆

    Board addition of Julie Boland brings financial and governance expertise; potential positive governance signal

  • Xeris Biopharma↓ (OPPORTUNITY)
    ◆

    Board addition of Menassie Taddese brings global commercial and financial expertise; potential strategic guidance

  • ◆

    Permanent CFO Sandeep Deoji appointed after interim period; internal promotion provides continuity

  • Lindsay Corporation↓ (OPPORTUNITY)
    ◆

    Permanent CFO Michael Koch appointed effective Nov 9, ending interim arrangement; brings 30 years finance experience

Sector Themes (6)

  • CFO Turnover Wave
    ◆

    9 companies announced CFO changes (Keysight, Upwork, Ur-Energy, Syndax, Lindsay, PG&E, CSB, Coronado, TE Connectivity), with effective dates spanning Nov 2026 to Apr 2027; many are planned retirements or internal promotions, suggesting orderly succession but potential for strategic shifts

  • CEO Succession Activity
    ◆

    6 CEO transitions (Telos, CVG, Fluence, FHLB Chicago, Apogee, Lennox segment) plus interim arrangements; several involve long-tenured leaders stepping down (Telos 32 years, FHLB Chicago 20+ years), signaling a generational shift in leadership

  • Board Refreshment
    ◆

    12 board changes, mostly appointments of independent directors with financial, accounting, or industry expertise (Deere, 10x Genomics, Intuitive Surgical, PVH, Xeris, ZipRecruiter); average board size increased, and committee reconstitutions were common

  • Divergent Operating Performance
    ◆

    Q3 2026 results show a wide gap: Hinge Health (+52% revenue, 21% operating margin) and Syndax (+82% revenue) outperformed, while Upwork (-9% marketplace revenue, -10% clients) and CVG (adjusted net income only $1.2M) lagged; margin trends varied from +300 bps (CVG) to -115 bps (Upwork)

  • Severance and Retention Focus
    ◆

    Advantage Solutions enhanced change-in-control severance for four NEOs; Elme Communities terminated retention agreements with cash payouts; Apogee extended CEO with transition bonus; companies are proactively managing leadership transitions with financial protections

  • Strategic Misalignment Risk
    ◆

    Anavex Life Sciences’ three director resignations citing strategic direction misalignment highlight governance risk; contrasts with routine retirements elsewhere, indicating potential for activist or strategic shifts

Watch List (8)

  • Q4 FY2026 results on Nov 19; CFO transition effective Dec 18; watch for guidance and demand trends

  • Q3 2026 results on Nov 9; new CEO Mark Griffin; watch for strategic updates

  • New CEO David Ruppel effective Nov 9; watch for integration and margin progress

  • New CFO Aaron Ondrey effective Nov 9; watch for pipeline updates and commercial execution

  • Registrational REC-4881 trial expected H2 2027; partnership discussions for REC-617 and REC-3565; watch for deal announcements

  • Board reconstitution and strategic direction; potential further governance changes; monitor for activist involvement

  • Search for permanent CEO; interim CEO Axel Meier’s transition; watch for strategic review

  • Search for permanent CEO; Nolan’s extended term through Apr 2027; watch for succession announcement

Filing Analyses (39)
Predictive Oncology Inc. 8-K neutral materiality 5/10

02-11-2026

Axe Compute Inc. (filed under Predictive Oncology Inc./POAI, now trading as AGPU on Nasdaq) disclosed that three directors — Chairman Charles L. Nuzum, Daniel E. Handley and Gregory S. St. Clair — resigned effective October 27, 2026, with no stated disagreement, leaving a four-member board (three independent) and three vacancies. CEO Christopher Miglino was appointed Chair effective November 1, 2026 with no additional compensation, and the company entered consulting agreements with the departing directors, paying Handley $120,000 cash and granting Nuzum and St. Clair restricted stock valued at $150,000 each, plus retainer/committee fees through December 31, 2026. The board changes follow the Q3 2026 divestiture of the legacy Helomics subsidiary, with the company evaluating candidates to fill vacancies.

  • · All three resignations were effective October 27, 2026, and were not the result of any disagreement with the company.
  • · The Audit, Compensation and Nominating and Governance Committees were reconstituted on November 2, 2026 to maintain Nasdaq composition requirements.
  • · Each departing director will also receive the cash retainer and committee fees he would have earned through December 31, 2026.
  • · Restricted shares granted to Nuzum and St. Clair vest in full six months after the effective date of their consulting agreements.
  • · Consulting agreements will be filed as exhibits to the company's Form 10-K for the year ending December 31, 2026.
  • · The company relocated its principal executive offices to 801 Brickell Avenue, Suite 510, Miami, Florida 33131, from Pittsburgh, Pennsylvania.
  • · The company is in advanced stages of evaluating candidates to fill the three board vacancies.
Keysight Technologies, Inc. 8-K neutral materiality 6/10

02-11-2026

Keysight Technologies announced a planned CFO succession: Jason Kary, currently SVP and President of the Electronic Industrial Solutions Group, will become CFO effective December 18, 2026, succeeding Neil Dougherty, who has served as CFO for 13 years and been with the company 30 years. Dougherty will remain in an advisory capacity through fiscal 2027 to support the transition. The company did not update its Q4 FY2026 outlook, stating demand across end markets remains strong, with results scheduled for November 19, 2026.

  • · Effective date of Kary's CFO appointment is December 18, 2026
  • · Following Kary's appointment, the Electronic Industrial Solutions Group will report to Kailash Narayanan while remaining a separately reported financial segment
  • · Keysight will report Q4 FY2026 results (quarter ended October 31, 2026) on Thursday, November 19, 2026
  • · Kary joined HP in 1996 and held finance roles through the company's evolution into Agilent and Keysight
  • · Kary holds an MBA from Carnegie Mellon University and a bachelor's degree from the University of Illinois, Urbana-Champaign
UPWORK, INC 8-K mixed materiality 8/10

02-11-2026

Upwork reported Q3 2026 revenue of $185.6 million with GAAP net income of $31.8 million (+8% YoY) and adjusted EBITDA of $63.8 million (34.4% margin, +7% YoY). However, GSV declined 10.1% YoY to $914.1 million, marketplace revenue fell 9% to $159.3 million, active clients dropped 10% to 717,000, and free cash flow fell 22% to $53.9 million. The company also announced Lifted's acquisition of Berlin-based EOR provider WorkMotion and a CFO transition, with Erica Gessert stepping down January 1, 2027, to be succeeded by Chief Business Officer Peter Sanborn.

  • · Gross profit margin declined 115 bps YoY to 76% in Q3 2026
  • · Nine-month 2026 net income fell 11% YoY to $88.7 million
  • · Nine-month 2026 free cash flow fell 38% YoY to $102.7 million
  • · Operating expenses declined 15% YoY to $106.7 million
  • · Q4 2026 adjusted EBITDA guidance of $51-55 million; non-GAAP diluted EPS of $0.30-0.32
  • · FY2026 non-GAAP diluted EPS guidance of $1.45-1.47
  • · 40% of Business Plus active clients had their first Upwork spend on Business Plus
  • · MCP server weekly active users up 20x since August launch
  • · Lifted signed three new enterprise logos and was named a leader in Everest Group's 2026 PEAK Matrix for CoR/CEoR
  • · Upwork has facilitated more than $30 billion in total transactions since founding
Elme Communities 8-K neutral materiality 6/10

02-11-2026

Elme Communities filed an 8-K disclosing the termination of retention agreements for three officers effective November 6, 2026, tied to the company's expected dissolution on that date under its previously approved Plan of Sale and Liquidation. Paul McDermott, Tiffany Butcher and W. Drew Hammond will receive cash lump sums of $5,062,631, $1,029,484 and $1,661,939 respectively. Separately, the NYSE filed a Form 25-NSE on October 26, 2026 to delist the shares, which began trading OTC under the symbol 'ELMES' that same day, with share transfer books set to close November 5, 2026.

  • · Board approved the Plan of Sale and Liquidation on July 30, 2025; shareholders approved it on October 30, 2025
  • · Retention agreements with the three officers were originally entered into on January 22, 2026
  • · Company expects to dissolve on November 6, 2026, with remaining assets and liabilities transferred to a Maryland common law trust (the Liquidating Trust)
  • · The Liquidating Trust is expected to enter into part-time, as-needed consulting agreements with Mr. Hammond and Ms. Butcher
  • · Share transfer books close at the close of business Eastern Time on November 5, 2026
  • · Common shares have par value $0.01 per share
  • · Risk factors reference potential legal proceedings related to the sale of 19 multifamily assets to an affiliate of Cortland Partners, LLC
Advantage Solutions Inc. 8-K neutral materiality 4/10

02-11-2026

Advantage Solutions amended employment agreements on October 30, 2026 with four named executive officers — CEO David Peacock, CFO Christopher Growe, COO Branded Services Jeffrey Harsh, and COO Retailer Services & Activation Michael Taylor — enhancing change-in-control severance protections. CEO Peacock receives 2x target annual bonus plus 100% accelerated equity vesting on a Change in Control Qualifying Termination, while Growe and Harsh receive 18 months base salary, 18 months COBRA, 1.5x target bonus, and full equity acceleration; Taylor receives 1.5x base salary plus target bonus over 18 months, a pro-rated bonus, outplacement, and full acceleration. No financial results, revenue, or operating metrics were disclosed, and no officer departures or appointments occurred despite the Item 5.02 designation.

  • · Taylor's COBRA coverage extended from nine months to 12 months following a Qualifying Termination
  • · Taylor also receives outplacement services and a pro-rated annual bonus based on actual results, benefits not granted to Growe or Harsh
  • · Growe and Harsh receive an 18-month post-termination exercise period for outstanding stock options
  • · Pre-Effective Date equity awards only qualify for acceleration if termination occurs within 24 months following a Change in Control
  • · Certain portions of the Harsh and Taylor agreements were redacted as confidential under Item 601(b)(10) of Regulation S-K
  • · Agreements filed as Exhibits 10.1-10.4 to the Form 8-K
DEERE & CO 8-K positive materiality 4/10

02-11-2026

Deere & Company appointed Julie Boland, former U.S. CEO and managing partner and Americas managing partner of Ernst & Young LLP, to its board of directors effective Nov. 2, 2026. The appointment expands the board from 10 to 11 members, including 10 independent, non-employee directors. Boland brings accounting, financial reporting, governance, and investment banking experience (JPMorgan, Goldman Sachs) and served at EY from 2022 to 2026 across more than 16 years at the firm.

  • · Boland served as EY's U.S. CEO and managing partner and Americas managing partner from 2022 to 2026
  • · Prior EY roles included vice chair, Central Region managing partner, and Cleveland office managing partner
  • · Before EY, Boland was CFO at public and private companies and worked in investment banking at JPMorgan & Co. and Goldman Sachs in New York, Chicago, and London
  • · Filing items: 5.02 (Director/Officer Departure/Election), 7.01 (Reg FD), 9.01 (Financial Statements and Exhibits)
  • · Company founded nearly 200 years ago with a steel plow
Global Indemnity Group, LLC 8-K neutral materiality 3/10

02-11-2026

Global Indemnity Group, LLC disclosed in an 8-K that Bruce Lederman resigned as a Fox Paine Designated Director effective October 26, 2026, vacating his roles as Chair of the Enterprise Risk Management Committee and member of the Audit and Conflicts Committees. Concurrently, Fox Paine appointed Jessica E. Buss as a Designated Director to the same Board, naming her Chair of the ERM Committee and a member of the Audit, Conflicts, and Nominating, Compensation and Governance Committees, with her term running from October 26, 2026 through December 31, 2026. Ms. Buss is not subject to stockholder election and will be compensated under the Company's non-executive director compensation plan; no financial terms or monetary amounts were disclosed.

  • · Ms. Buss's directorship term runs from October 26, 2026 until December 31, 2026
  • · Ms. Buss is a party to an agreement with the Class B Majority Shareholder and is not subject to election by the Company's stockholders
  • · Ms. Buss will be compensated under the non-executive director compensation plan described in the Definitive Proxy Statement on Schedule 14A filed April 29, 2026
  • · No arrangements or understandings exist between Ms. Buss and any other person regarding her selection, and she has no family relationship with any director or executive officer
  • · The 8-K was signed October 30, 2026 by Jo Cheeseman, Vice President & Corporate Secretary
  • · The news release was issued October 27, 2026 (Exhibit 99.1)
  • · The governing Third Amended and Restated Limited Liability Company Agreement is dated January 16, 2025, and was filed with the Form 10-K on March 10, 2026
10x Genomics, Inc. 8-K neutral materiality 4/10

02-11-2026

10x Genomics appointed Dr. Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors effective October 28, 2026, with terms expiring at the 2028 annual meeting. Gilliam, President and COO of Glaukos and former JPMorgan healthcare banker, was also named Audit Committee Chair on October 30, 2026. Both receive standard non-employee director compensation including a $60,000 annual cash retainer and a one-time $400,000 target-value RSU grant; no financial results or operating metrics were disclosed in this filing.

  • · Satpathy was a scientific advisor to 10x prior to joining the Board; the advisor agreement was terminated in October 2026 before his appointment
  • · Satpathy has been Associate Professor of Pathology and Immunology at Stanford since April 2024 and a venture partner at Wing Venture Capital since November 2021
  • · Gilliam has been President and COO of Glaukos since April 2022 and was its CFO/SVP Corporate Development from May 2017 to April 2022
  • · Gilliam sits on the board of Caris Life Sciences, serving on its audit and compensation committees
  • · One-time RSU grants vest one third on February 21, 2028, then quarterly over two years; annual grants vest quarterly starting the first Feb/May/Aug/Nov 21 after the annual meeting
  • · Both directors entered into the Company's standard indemnification agreement (form filed as Exhibit 10.17 to Form S-1/A on September 3, 2019)
  • · No financial results, guidance, or operating metrics were disclosed
DAILY JOURNAL CORP 8-K neutral materiality 5/10

02-11-2026

Daily Journal Corp disclosed new executive compensation agreements: a CEO Compensation Agreement with Chairman/CEO Steven Myhill-Jones (base salary $700,000 effective Oct 1, 2025, plus a one-time $475,000 cash award and 800 RSUs) and a CFO Letter Agreement with Erik Nakamura (base salary $400,000 effective Oct 1, 2026, up from prior terms, with a $200,000 bonus target and $100,000 LTI target). The CEO deal adds performance-linked incentives of 4% of operating income in cash (capped at 2x base salary) and 1% in equity (capped at 400 shares/year) for FY2026-2027, aligning pay with results while raising fixed and variable compensation costs.

  • · CEO cash incentive capped at two times annual base salary; equity incentive capped at 400 shares per fiscal year
  • · CEO must be actively employed from beginning through end of performance period to earn incentive compensation
  • · Operating income defined as consolidated pre-tax operating income under GAAP, before incentive compensation, excluding certain acquired/disposed businesses and extraordinary events
  • · CEO severance on termination without just cause: greater of statutory minimum notice or average of base salary, bonus and incentive over lookback period (1-3 fiscal years), paid over 12 months
  • · CEO equity awards accelerate on change in control per Plan terms
  • · CEO agreed to use reasonable efforts to give at least six months' advance notice of resignation
  • · CFO salary reviewed annually in July with adjustments effective October 1
  • · CFO bonus reduced by payments received through Profit Sharing (Units) Program
  • · CFO LTI awards vest in equal annual installments over three years
  • · CFO employment remains at will with no specified period
UR-ENERGY INC 8-K neutral materiality 4/10

02-11-2026

Ur-Energy announced that CFO Roger Smith will retire effective December 1, 2026, after a 45-year mining finance career, including nearly 20 years leading Ur-Energy's finance, IT, and administration teams. VP Finance Jade Walle, a CPA with 30 years of experience and a former PwC audit partner (2011–2024), was named successor effective upon Smith's retirement. The filing contains no financial results or monetary figures; it is a routine, orderly management succession disclosure.

  • · Roger Smith's retirement is effective December 1, 2026; Jade Walle's appointment as CFO is effective upon that retirement
  • · Jade Walle joined Ur-Energy as VP Finance in September 2025
  • · Walle was an audit partner at PwC from 2011 to 2024, having begun his career there in 1996
  • · Walle served in PwC's Global Capital Markets Group in London (1999–2002), assisting non-U.S. companies with U.S. capital market transactions and SEC reporting
  • · Walle held leadership roles overseeing a PwC Center of Excellence division and its Acceleration Center in India
  • · Ur-Energy describes itself as the largest and fastest-growing ISR uranium mining company in the United States
  • · Shirley Basin ISR mine launched full operations in August 2026
  • · Shares trade on NYSE American (URG) and TSX (URE); headquarters in Casper, Wyoming, registered office in Ottawa, Ontario
Syndax Pharmaceuticals Inc 8-K mixed materiality 8/10

02-11-2026

Syndax reported Q3 2026 total revenue of $83.3 million, up 82% year-over-year, driven by Revuforj net revenue of $60.7 million (+90% y/y, +11% q/q) and Niktimvo net revenue of $67.4 million (+47% y/y, +12% q/q), yielding $22.6 million in collaboration revenue. However, R&D expenses rose to $67.5 million from $56.3 million, and the company posted a net loss of $49.4 million ($0.55/share), though narrower than the $60.7 million ($0.70/share) loss a year ago; separately, the MAXPIRe Phase 2 trial of axatilimab in IPF failed its primary endpoint and development in that indication will be discontinued. The company also announced CFO Keith Goldan's retirement and the appointment of Aaron A. Ondrey as CFO effective November 9, 2026.

  • · MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint; Syndax will not pursue further development in IPF
  • · R&D expenses rose 19.9% y/y to $67.5M from $56.3M, driven by frontline revumenib AML trials
  • · SG&A expenses declined 2.7% y/y to $43.7M from $44.9M on lower launch costs
  • · Net loss narrowed 18.6% y/y to $49.4M ($0.55/share) from $60.7M ($0.70/share)
  • · Cash, cash equivalents and short- and long-term investments of $551.1M as of September 30, 2026, with 90.0 million common shares outstanding
  • · Full year 2026 guidance: total R&D plus SG&A of approximately $400M, excluding ~$50M non-cash stock compensation
  • · Revuforj received Best Product for Rare/Orphan Diseases award from The Galien Foundation and was named a TIME Best Invention of 2026
  • · New revumenib data expected in Q4 2026 across BEAT AML, SAVE, intensive chemotherapy, post-transplant maintenance, INTERCEPT and real-world evidence
  • · RAVEN Phase 2 trial expected to initiate Q4 2026; MenTain Phase 2 trial expected Q1 2027
  • · SNDX-4321 IND submission expected by end of 2026 with Phase 1 in EGFRm NSCLC in 2027; SNDX-62122 IND and Phase 1 in myelofibrosis expected Q4 2027
  • · Axatilimab Phase 2 (with ruxolitinib) topline data expected Q1 2027; Phase 3 (with corticosteroids) topline expected early 2028
  • · CFO transition: Keith Goldan retiring; Aaron A. Ondrey appointed CFO effective November 9, 2026
ZIPRECRUITER, INC. 8-K neutral materiality 4/10

02-11-2026

ZipRecruiter appointed Jeffrey Liaw, former CEO of Copart, to its Board of Directors and announced the resignation of director Emily McEvilly, both effective October 29, 2026. CEO Ian Siegel highlighted Liaw's nearly decade of CFO, President, and CEO experience at Copart as bringing financial discipline and marketplace operational expertise. The filing contains no financial results or monetary figures, and the board change is a single seat swap with no disclosed change to board size or committee composition.

  • · Jeffrey Liaw served as CEO and board member of Copart from April 2024 to July 2026
  • · Liaw held prior Copart roles: Co-CEO (Apr 2022–Apr 2024), President & CEO North America (Feb 2021–Apr 2022), President (Sep 2019–Jan 2021), CFO (Sep 2016–Oct 2020)
  • · Liaw was CFO of FleetPride, Inc. from 2013 to 2015 and a principal at TPG Capital from 2005 to 2013
  • · Liaw holds a B.A. in Plan II Liberal Arts and B.B.A. in Finance from University of Texas at Austin and an M.B.A. from Harvard Business School
  • · Appointment and resignation both effective October 29, 2026
  • · ZipRecruiter has been #1 rated job search app on iOS & Android for the past nine years and rated #1 employment job site by G2
Fluence Energy, Inc. 8-K neutral materiality 5/10

02-11-2026

Fluence Energy's Board approved Axel Meier as Interim President & CEO effective November 2, 2026, at an annual base salary of $1,015,000, as the company transitions to a permanent chief executive. The appointment is explicitly interim — Meier receives a discretionary bonus contingent on completing the transition and placing a permanent President & CEO, and notably is excluded from the Executive Severance Plan given the interim nature of the role. The filing discloses no financial results or operating metrics, so there is no period-over-period performance data to assess.

  • · Meier is not designated a participant in the Fluence Executive Severance Plan and is ineligible for severance thereunder
  • · Discretionary cash bonus tied to successful transition and placement of a permanent President & CEO, subject to Board approval
  • · Employment is 'at will' under Virginia law; offer letter does not constitute an employment contract
  • · 401(k): employee may contribute up to 50% of salary; company matches 100% up to 5% of gross salary
  • · Offer letter dated October 30, 2026; signed by Meier November 1, 2026; effective November 2, 2026
  • · Meier subject to officer-specific policies including the clawback policy
GREYSTONE LOGISTICS, INC. 8-K neutral materiality 3/10

02-11-2026

Greystone Logistics, Inc. disclosed in an 8-K that director Larry J. LeBarre retired from the Board of Directors effective October 30, 2026, after serving since May 5, 2012. The Company stated the retirement is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. No financial figures, replacement director, or compensatory arrangements were disclosed in the filing.

  • · Larry J. LeBarre served as a director of Greystone Logistics from May 5, 2012 until his retirement on October 30, 2026, a tenure of approximately 14 years
  • · The filing does not name a successor director or disclose any compensatory arrangements related to the departure
  • · The 8-K was signed by Warren F. Kruger, who holds the combined roles of President, CEO, CFO, and Chairman of the Board
  • · No securities are registered under Section 12(b) of the Act, per the filing cover page
Federal Home Loan Bank of Chicago 8-K neutral materiality 6/10

02-11-2026

Federal Home Loan Bank of Chicago announced that President and CEO Michael A. Ericson will conclude his tenure effective December 31, 2026, after more than 20 years of service. The Board appointed Virxhini Gjonzeneli, currently EVP, CFO and Group Head of Financial Accounting and Markets, as interim President and CEO effective January 1, 2027, while initiating a comprehensive search for a permanent CEO. No financial figures or period-over-period metrics were disclosed in the filing.

  • · Gjonzeneli has served as CFO and Group Head, Financial Accounting and Markets since 2023
  • · Gjonzeneli was named Executive Vice President in 2021
  • · Gjonzeneli previously served as Group Head of Member Support and Strategy and Senior Vice President, Director of Enterprise Risk Management
  • · Gjonzeneli serves on the boards of Legal Aid Chicago, Chicago Commons, and the Chicago Public Library Foundation
  • · FHLBank Chicago is a self-capitalizing cooperative owned by Illinois and Wisconsin members, including commercial banks, credit unions, insurance companies, savings institutions and community development financial institutions
  • · Filing includes Items 5.02 (officer departure/election), 7.01 (Reg FD) and 9.01 (financial statements and exhibits)
Hinge Health, Inc. 8-K positive materiality 9/10

02-11-2026

Hinge Health reported record Q3 2026 revenue of $235.0 million, up 52% year-over-year from $154.2 million, with GAAP operating income swinging to $50.3 million (21% margin) from a $6.1 million loss, and free cash flow of $112.7 million (48% margin). Full-year 2026 revenue guidance was raised to a $880 million midpoint (+50% YoY) and non-GAAP operating margin guidance to a 30% midpoint (~1,000 bps improvement). However, operating expense growth outpaced revenue in some lines (R&D +17%, sales & marketing +34%), and the company also disclosed that President Jim Pursley will step down effective January 1, 2027, joining the Board, with Aaryn Pure elevated to Chief Commercial Officer.

  • · GAAP gross margin improved to 87% from 82%; non-GAAP gross margin to 88% from 83%
  • · Q3 2026 GAAP net income of $57.4M vs net loss of $1.8M in Q3 2025
  • · Nine-month 2026 revenue $630.1M vs $417.1M in 2025
  • · Nine-month 2026 net income $136.2M vs net loss of $560.4M in 2025
  • · Cash, cash equivalents, marketable securities and restricted cash of $358.5M as of Sept 30, 2026
  • · Deferred revenue rose to $459.2M from $300.9M at Dec 31, 2025
  • · Goodwill increased to $113.0M from $64.1M, reflecting Cylinder Health acquisition
  • · Q3 2026 stock-based compensation fell to $19.5M from $34.8M in Q3 2025
  • · Jim Pursley steps down as President effective Jan 1, 2027 and joins Board Jan 4, 2027; Aaryn Pure becomes Chief Commercial Officer
  • · Q4 2026 non-GAAP operating margin guidance of 33% at midpoint, ~470 bps increase over Q4 2025
  • · Full year 2026 non-GAAP operating margin guidance of 30% at midpoint, ~1,000 bps improvement over 2025
AbbVie Inc. 8-K neutral materiality 3/10

02-11-2026

AbbVie Inc. disclosed in an 8-K (Item 5.02) that Class II director Jennifer L. Davis resigned from the Board effective November 2, 2026, following her appointment as Chief Executive Officer of Align Technology, Inc. The company stated the resignation is not the result of any dispute or disagreement with AbbVie on operations, policies or practices. No financial terms, compensatory arrangements, or replacement director were disclosed.

  • · Resignation notice given October 28, 2026; effective date November 2, 2026
  • · Davis is a Class II director of AbbVie
  • · Reason cited: her recent appointment as Chief Executive Officer at Align Technology, Inc.
  • · AbbVie explicitly stated the resignation is not due to any dispute or disagreement on operations, policies or practices
  • · Filing signed by Perry C. Siatis, Executive Vice President, General Counsel and Secretary, dated November 2, 2026
  • · No successor director, committee reassignment, or compensatory arrangement was disclosed
Frontier Group Holdings, Inc. 8-K neutral materiality 5/10

02-11-2026

Frontier Airlines (NASDAQ: ULCC) announced the appointment of Michael Delehant, formerly Group Managing Director of Wizz Air, as Executive Vice President and Chief Operating Officer effective November 30, 2026, reporting to CEO Jimmy Dempsey. In the same leadership reshuffle, James Fenner was promoted to SVP and Chief Revenue Officer and Bobby Schroeter moved to SVP and Chief Marketing Officer, while SVP Operations Trevor Stedke and SVP Customers Alex Clerc will leave the company effective November 13, 2026. The filing contains no financial results or guidance, so no period-over-period metrics were disclosed.

  • · Delehant's prior roles: Group Managing Director at Wizz Air; Chief Strategy and Network Officer at Vueling; leadership positions at Southwest Airlines
  • · Delehant holds a BA in Psychology from the University of Michigan and an MBA from Southern Methodist University
  • · Fenner has served Frontier for more than 10 years, most recently as Vice President of Revenue and Loyalty; new scope includes Pricing and Revenue Management, Loyalty and Network Planning
  • · Schroeter's new scope covers Brand and Customer Experience
  • · Both Fenner and Schroeter report to CEO Jimmy Dempsey
  • · Departures of Stedke and Clerc take effect November 13, 2026, ahead of Delehant's November 30, 2026 start
  • · Filing items: 5.02 (officer departure/election), 7.01 (Reg FD), 9.01 (financial statements/exhibits)
INTUITIVE SURGICAL INC 8-K neutral materiality 4/10

02-11-2026

Intuitive Surgical appointed Aaron Martin, currently President of Insurance at Humana, to its board of directors effective January 1, 2027, expanding the board from 10 to 11 members. Martin brings payer, digital health, and venture experience from Humana, Amazon (where he launched Amazon Clinic), and Providence St. Joseph Health, but the appointment is subject to his continued willingness and ability to serve. No financial results or guidance were disclosed in this filing.

  • · Appointment effective January 1, 2027, subject to Martin's continued willingness and ability to serve
  • · Martin reports to Humana's CEO and serves on the Humana Enterprise Leadership Team
  • · Martin held board roles at Kyruus, Wildflower Health, Xealth, DexCare, AVIA, and Presbyterian Health System
  • · Martin holds a BA from Austin College and an MBA from the Wharton School
FEMASYS INC 8-K neutral materiality 3/10

02-11-2026

Femasys Inc. (NASDAQ: FEMY) appointed John Moorhead to its Board of Directors as the board designee tied to the Company's August 2026 private placement, replacing Dr. Kenneth Eichenbaum, who had served as designee for the November 2025 private placement. Moorhead brings over two decades of consumer marketing, brand development, product innovation and finance experience, including 12 years at Unilever's Seventh Generation where he rose to Chief Marketing Officer, and most recently Head of Marketing, North America, at SBM Life Science. The company framed the appointment as support for ramping commercialization of its FemaSeed fertility portfolio, while FemBloc remains pre-approval in the U.S. pending the ongoing FINALE pivotal trial (NCT05977751).

  • · Moorhead helped more than quadruple Seventh Generation's Home Care business during his tenure
  • · FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025
  • · FemBloc remains pre-approval in the U.S., pending the ongoing FINALE pivotal trial
  • · Board seat is tied to the August 2026 private placement, replacing the designee from the November 2025 private placement
  • · Femasys trades on NASDAQ under ticker FEMY
LINDSAY CORP 8-K neutral materiality 4/10

02-11-2026

Lindsay Corporation appointed Michael Koch as Senior Vice President and Chief Financial Officer effective November 9, 2026, ending an interim CFO arrangement in place since September 2026. Koch brings nearly 30 years of finance experience, most recently as SVP Finance and Divisional CFO of StandardAero's Commercial Engine Services division, and previously held finance leadership roles at Universal Electronics, Nortek Security & Control and Ryan Herco Flow Solutions. Interim co-CFOs Brett Coburn and Alicia Pfeifer, who filled the role since September 2026, will remain in their existing vice president roles; the filing contains no financial results or performance metrics.

  • · Koch's appointment is effective November 9, 2026
  • · Interim co-CFO arrangement began September 2026
  • · Koch joined StandardAero in 2025 and held finance roles at Universal Electronics beginning in 2004
  • · Lindsay was established in 1955 and trades on NYSE under LNN
  • · Company contact numbers listed: 402-829-6800 (phone) and 402-829-6836 (fax); Alpha IR contact 312-445-2870
LENNOX INTERNATIONAL INC 8-K neutral materiality 5/10

02-11-2026

Lennox announced a leadership transition in its Building Climate Solutions segment: Joe Nassab, EVP and President, will step down from the role at the end of 2026 and remain as a strategic advisor, with Geoff Dethlefsen (currently VP/GM of Lennox Commercial HVAC) assuming segment leadership effective January 1, 2027. The release cites Dethlefsen's record of revenue and margin growth, improved operations, and the opening of a new Saltillo manufacturing facility, but provides no financial figures or quantitative performance data for the segment or company. No negative or declining metrics were disclosed; the filing is a qualitative management change announcement.

  • · Nassab joined Lennox in 2010 as VP and GM of Allied Air and was named to lead the North American Commercial Heating and Cooling segment in 2022 (later renamed Building Climate Solutions)
  • · Nassab's transition from his role occurs at the end of 2026; Dethlefsen's appointment is effective January 1, 2027
  • · Dethlefsen joined Lennox in 2024 with more than 20 years of leadership experience in industrial manufacturing, strategy, and business operations
  • · Dethlefsen previously served as President of Hammerforce USA and President of Professional Grade Trailers (a division of American Trailer World), with prior roles at Flowserve Corporation and Boston Consulting Group
  • · Dethlefsen holds bachelor's degrees in mechanical engineering and Spanish from Rice University and an MBA from The University of Texas at Austin
  • · No financial figures, revenue, margin, or guidance numbers were disclosed in the release
PVH CORP. /DE/ 8-K neutral materiality 3/10

02-11-2026

PVH Corp. announced the appointment of Frits Dirk van Paasschen to its Board of Directors, effective immediately, as part of the Board's ongoing refreshment process. The filing contains no financial results or monetary figures; it is a governance update highlighting van Paasschen's prior CEO experience at Starwood Hotels and Coors Brewing and board roles at DSM-Firmenich, Amadeus IT Group, and Williams-Sonoma. No departures, financial guidance, or performance metrics were disclosed.

  • · van Paasschen spent more than a decade as CEO at Fortune 500 consumer and lifestyle companies
  • · He previously served as General Manager of Nike's EMEA region, where he helped grow revenue and double profits
  • · He held a leadership role in Disney's Consumer Products Division
  • · He holds a BA in Economics and Biology from Amherst College and an MBA from Harvard Business School
  • · Until recently he served on the board of J.Crew
  • · No financial terms, compensation, or equity grants were disclosed in the filing
ANAVEX LIFE SCIENCES CORP. 8-K negative materiality 7/10

02-11-2026

Three directors of Anavex Life Sciences — Chair Dr. Jiong Ma, Gautam Patel, and Dr. Adrian Senderowicz — resigned from the Board effective October 28, 2026, each citing that their views on the Company's strategic direction and business plan execution do not sufficiently align with the Board and management. The departures removed the Audit Committee Chair (Ma) and a second Audit Committee member (Patel), prompting the Board on November 1, 2026 to reconstitute all three standing committees. No financial figures or period-over-period metrics were disclosed in this filing.

  • · All three resignations were effective the same day they were submitted, October 28, 2026.
  • · Dr. Ma's stated reason: her views on the Company's strategic direction are not fully aligned with the Board and management.
  • · Mr. Patel and Dr. Senderowicz each stated their personal views on the Company's strategy to execute its business plan do not sufficiently align with the Board and management.
  • · Dr. Senderowicz did not serve on any Board committees prior to resigning.
  • · The Company gave each departing director the opportunity to submit a letter disagreeing with the Company's disclosures; any such letter will be filed as an exhibit within two business days of receipt.
  • · Post-reconstitution, the Audit Committee consists of Dr. Claus van der Velden (Chair), Dr. Peter Donhauser, and Dr. Axel Paeger.
  • · The Compensation Committee consists of Dr. Peter Donhauser (Chair) and Dr. Claus van der Velden.
  • · The Nominating & Corporate Governance Committee consists of Dr. Axel Paeger (Chair) and Dr. Peter Donhauser.
  • · The 8-K was signed by Sandra Boenisch, Principal Financial Officer and Treasurer, and dated November 2, 2026.
  • · Company headquarters: 630 5th Avenue, 20th Floor, New York, NY 10111; Nevada incorporation; Commission File Number 001-37606.
RECURSION PHARMACEUTICALS, INC. 8-K mixed materiality 8/10

02-11-2026

Recursion reported Q3 2026 results, extending its cash runway into 2029 (including October 2026 follow-on offering proceeds) while reiterating 2026 cash opex guidance of less than $375 million and setting 2027 guidance of less than $360 million. Clinical updates were positive: REC-4881 Phase 2 TUPELO data showed 87% of patients (13/15) with reduced total polyp burden and a 47% median reduction, with 85% remaining below baseline 12 weeks off treatment; REC-1245 showed a 91.7% disease control rate (11/12) at doses ≥45 mg with 2 confirmed and 1 unconfirmed partial responses. However, the company is deprioritizing REC-617 (CDK7) and REC-3565 (MALT1) to pursue partnerships, and a registrational REC-4881 trial is not expected until H2 2027, with REC-1245 expansion data also not until H2 2027. Sanofi optioned the first collaboration development candidate, triggering a $10 million milestone (total $144 million to date), and Fred Hassan was appointed Board Chair effective October 31, 2026.

  • · REC-4881: 6 of 8 patients with polyps >5 mm at baseline had fewer such polyps after 12 weeks; four achieved ≥80% reductions, two fell from more than 90 polyps to one.
  • · REC-4881: half (6/12) of upper GI patients improved by at least one Spigelman stage; two achieved ≥98% reductions.
  • · REC-4881: 70% of evaluable lower GI patients remained below baseline 12 weeks after stopping treatment.
  • · REC-4881 registrational trial anticipated to initiate in H2 2027, pending FDA discussions.
  • · REC-1245: 45 mg QD selected for exploratory expansion; no DLTs or treatment-related SAEs at 45 mg (n=10); most frequent TRAEs were Grade 1/2 fatigue and anemia (30% each).
  • · REC-1245 preliminary dose expansion data in endometrial cancer expected H2 2027.
  • · REC-1245 identified within 18 months after screening only 204 compounds.
  • · Recursion intends to pursue partnership opportunities for REC-617 (CDK7) and REC-3565 (MALT1), deprioritizing internal development.
  • · Genentech exercised first Validated Target Option under neuroscience collaboration in Q3 2026.
  • · Sanofi collaboration has achieved six progress-based milestones across five programs; candidate expected to enter Phase 1 in 2027.
  • · Roche/Genentech collaboration includes up to 40 potential small molecule discovery programs with tiered royalties up to high single digits.
TELOS CORP 8-K neutral materiality 6/10

02-11-2026

Telos Corporation appointed Executive Vice President Mark Griffin as CEO effective November 2, 2026, with longtime CEO John B. Wood (CEO since 1994) transitioning to Executive Chairman and stepping away from day-to-day operations. The Board framed the succession as continuity, citing the company's 'turnaround and return to growth' under Wood and Griffin's 35-year tenure and operational track record. No financial figures were disclosed; Q3 2026 results are scheduled for November 9, 2026.

  • · Q3 2026 financial results to be reported Monday, November 9, 2026, with webcast at 9:30 a.m. ET
  • · Griffin previously served as EVP of Security Solutions, leading market expansion, product development and IP portfolio management
  • · Wood will remain Chairman of the Board and focus on product roadmap and long-term sales strategy
  • · No financial terms, compensation details, or performance metrics disclosed in the filing
Greenlane Holdings, Inc. 8-K neutral materiality 3/10

02-11-2026

Greenlane Holdings appointed Peter Kampian, a Chartered Professional Accountant with over 30 years of CFO and board experience, as an independent director effective October 27, 2026, expanding the Board to four directors. The filing is a routine governance update with no financial figures, no disclosed compensation or equity grants, and no changes to executive management; the company also reiterated its digital asset treasury strategy focused on accumulating BERA, the Berachain native token.

  • · Appointment effective October 27, 2026; 8-K filed November 2, 2026
  • · Kampian determined independent under Nasdaq listing standards
  • · Kampian chairs the audit committee of Aduro Clean Technologies (Nasdaq: ADUR; TSX: ACT)
  • · Kampian has been a director of Matador Technologies (TSXV: MATA), a bitcoin ecosystem and treasury company, since 2024
  • · Kampian previously served as a director of Statehouse Holdings Inc. (formerly Harborside Inc.)
  • · Kampian holds CPA, CA and ICD.D designations
  • · No compensation, equity award, or committee assignment details disclosed
  • · No executive officer departure disclosed despite Item 5.02 filing
Commercial Vehicle Group, Inc. 8-K mixed materiality 8/10

02-11-2026

CVG reported Q3 2026 revenues of $208.1 million, up 36.5% YoY from $152.5 million, driven by increased demand across all three segments, with gross margin expanding 300 bps to 13.5% and a return to positive GAAP net income of $5.6 million ($0.14/diluted share) versus a $6.8 million loss. However, adjusted net income was only $1.2 million ($0.03/share) and GAAP results were boosted by a $4.1 million warrant revaluation benefit and a $3.1 million asset sale gain, while higher SG&A (share-based comp, incentive comp, CEO succession recruiting costs) partially offset gains. The company raised its full-year revenue outlook to $755-$775 million but narrowed the top end of Adjusted EBITDA guidance down to $26-$29 million, and announced David Ruppel will succeed James Ray as President and CEO effective November 9, 2026.

  • · Adjusted operating margin improved to 2.7% from 1.0% YoY
  • · Operating margin was 3.7% vs (0.7)% prior year
  • · Global Seating operating income $3.6M vs $1.4M; adjusted operating income $4.6M vs $2.9M
  • · Global Electrical Systems operating income $3.7M vs $0.8M
  • · Trim Systems operating income $5.8M vs operating loss of $0.9M; adjusted operating income $2.7M vs adjusted operating loss of $0.3M
  • · Net leverage reduced to approximately 2.7x
  • · Prior 2026 revenue outlook was $725-$755M; updated to $755-$775M
  • · Prior Adjusted EBITDA outlook was $26-$31M; updated to $26-$29M
  • · Free cash flow expected to remain positive
  • · James Ray's resignation was not due to any disagreement with the company
  • · David Ruppel brings 25+ years of operational and general management experience
  • · Conference call scheduled November 3, 2026 at 8:30 a.m. ET
PodcastOne, Inc. 8-K neutral materiality 4/10

02-11-2026

PodcastOne, Inc. disclosed in an 8-K that director Ramin Arani resigned from the board effective October 27, 2026, for personal reasons, vacating seats on the Audit, Compensation and Nominating Committees. The company stated the resignation was not due to any disagreement over operations, policies or practices, and said it expects to appoint one or more existing independent directors to the committees while conducting a search for a qualified new board candidate.

  • · Resignation effective date and event date: October 27, 2026; 8-K filed November 2, 2026
  • · Company is a Delaware corporation, EIN 35-2503373, SEC file number 001-41795, fiscal year end March 31
  • · Company qualifies as an emerging growth company
  • · Former name Courtside Group, Inc., changed in July 2022
  • · Principal executive offices: 345 North Maple Drive, Suite 295, Beverly Hills, CA 90210
LiveOne, Inc. 8-K neutral materiality 3/10

02-11-2026

LiveOne, Inc. disclosed in an 8-K that director Ramin Arani resigned from the board effective October 27, 2026, for personal reasons, and he also vacated his seat on the Audit Committee. The company stated the resignation was not due to any disagreement over operations, policies, or practices. To fill the vacancy, LiveOne expects to appoint one or more existing independent directors to the Audit Committee and will conduct a search for a qualified new board candidate.

  • · Resignation effective date: October 27, 2026; 8-K filed November 2, 2026
  • · Arani served on the Audit Committee at the time of resignation
  • · Company is a Delaware corporation, CIK 0001491419, file number 001-38249, fiscal year end March 31
  • · Formerly known as LiveXLive Media, Inc. (name change August 8, 2017) and LOTON, Corp (name change May 10, 2010)
  • · 8-K signed by CEO Robert Ellin
  • · Company is not an emerging growth company
Tivic Health Systems, Inc. 8-K mixed materiality 6/10

02-11-2026

Valion Bio, Inc. (NASDAQ: VBIO) announced that NIAID/RNCP, under an Interagency Agreement with USU/AFRRI, will advance Entolimod into a fully funded therapeutic efficacy study evaluating gastrointestinal acute radiation syndrome (GI-ARS) following recent positive safety results. The study will dose mice 24 hours after radiation exposure and monitor survival over 30 days, with top-line results anticipated in early December. However, the filing contains no financial figures, and the outcome remains binary and uncertain, with the company also flagging risks around capital needs and continued Nasdaq listing.

  • · Entolimod has received Fast Track and Orphan Drug designations from the FDA
  • · Valion holds an exclusive, worldwide license from Statera Biopharma to develop and commercialize Entolimod for ARS, radiation-induced neutropenia, and other indications
  • · Study primary endpoint is survival, comparing Entolimod-treated versus saline control groups
  • · Valion's wholly owned subsidiary Velocity Bioworks is a biologics CDMO supporting its internal pipeline
  • · Company cites risks including ability to obtain additional capital and continued listing on the Nasdaq Capital Market
  • · Annual Report on Form 10-K for year ended December 31, 2025 was filed with the SEC on March 30, 2026
Xeris Biopharma Holdings, Inc. 8-K positive materiality 4/10

02-11-2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) appointed Menassie M. Taddese to its Board of Directors effective November 2, 2026, and he will also serve on the Board's Audit Committee. Taddese brings nearly 30 years of biopharmaceutical leadership experience, most recently as President, Emerging Markets at Viatris, where he led an approximately $3 billion business across more than 125 markets, and previously spent over 20 years at Pfizer, including as CFO of an approximately $8 billion business. The appointment adds global commercial, financial, and public company governance expertise to the Board; no financial results or performance metrics were disclosed in this filing.

  • · Taddese most recently served as President, Emerging Markets at Viatris, leading an approximately $3 billion business across more than 125 markets with approximately 3,500 employees
  • · At Viatris he led integration of the Mylan and Upjohn businesses and expanded operating margins
  • · He spent more than 20 years at Pfizer, including as VP and CFO of the Global Innovative Pharma Segment North America, an approximately $8 billion business
  • · He serves as an independent director and Chair of the Audit Committee at Medexus Pharmaceuticals (TSX: MDP)
  • · Xeris has three commercial products: Recorlev®, Gvoke®, and Keveyis®
  • · Pipeline is led by XP-8121, a Phase 3-ready once-weekly subcutaneous injection for hypothyroidism
  • · Taddese holds an MBA in Finance with distinction from Penn State Smeal College of Business and completed an Executive Program at Columbia Business School
Coronado Global Resources Inc. 8-K neutral materiality 3/10

02-11-2026

Coronado Global Resources Inc. appointed Sandeep Deoji, its Interim CFO since August 1, 2026, as permanent Chief Financial Officer effective November 1, 2026, per an 8-K filed November 2, 2026. Deoji, age 42, will receive an annual base salary of AU$675,000 (inclusive of Australian statutory superannuation) under an employment agreement with subsidiary Curragh Queensland Mining Pty Ltd, and remains principal accounting officer. The appointment is an internal promotion with no disclosed related-party transactions or family relationships; no financial results or operating metrics were reported.

  • · Deoji served as Interim CFO from August 1, 2026 and previously as VP, Group Financial Control (July 2022–July 2026), Group Financial Controller (May 2021–July 2022), and Manager, Group Financial Reporting (January 2019–May 2021)
  • · Deoji served as interim principal financial officer and interim principal accounting officer from January 2025 to March 2025
  • · Deoji has been a Director of Wiggins Island Coal Export Terminal Pty Limited since June 2025
  • · STI bonus split: part paid on the 2027 STI payment date, part paid after completion of the audit of the Company's 2027 financial accounts
  • · Termination for cause carries no notice period; redundancy triggers payments under Australian legislation
  • · Employment Agreement dated October 30, 2026 (Australia) filed as Exhibit 10.1
  • · Company's securities have no registered class on any exchange (Title of class: None; Symbol: None)
PACIFIC GAS & ELECTRIC Co 8-K neutral materiality 4/10

02-11-2026

Pacific Gas and Electric Company's Board appointed Margaret K. Becker, 44, as Vice President, Operations Finance and Chief Financial Officer of the Utility, effective January 1, 2027. Becker has served as Treasurer of PG&E Corporation and the Utility since April 2020 and as Vice President, Treasurer since May 2021. In related moves effective the same date, Kristin Manz becomes Vice President, Treasurer and Insurance, while Stephanie N. Williams becomes Vice President, Chief Accounting Officer and Controller of PG&E Corporation and the Utility.

  • · All three officer changes take effect January 1, 2027, following the October 29, 2026 Board appointment.
  • · Becker has been responsible for PG&E Corporation's and the Utility's financing activities, treasury operations, accounts payable, and investment management functions.
  • · The filing states there are no arrangements or understandings between Becker and any other person regarding her selection, no family relationships with any director or executive officer, and no reportable transactions under Item 404(a) of Regulation S-K.
  • · All eight series of first preferred stock (PCG-PA through PCG-PI) are listed on NYSE American LLC.
  • · The 8-K was signed by John R. Simon, Executive Vice President, General Counsel, Chief Ethics & Compliance Officer and Corporate Secretary, dated November 2, 2026.
MID PENN BANCORP INC 8-K neutral materiality 4/10

02-11-2026

Mid Penn Bancorp subsidiary Mid Penn Bank announced the appointment of Scott W. Micklewright as chief operating officer, effective immediately, alongside a broader executive leadership reshuffle. Heather Hall was named president of the western division, Margaret Steinour became chief operations officer, and Heather Petito-Bentley was named chief administrative officer. The filing contains no financial results or performance metrics; it is a personnel/leadership update only.

  • · Micklewright will oversee loan, deposit and treasury services operations, human resources and administration, credit underwriting and credit administration, retail banking, and residential mortgage lending
  • · Hall's western division covers Dauphin, Cumberland, Lancaster, Berks, Schuylkill, Luzerne, Clearfield, Centre, Fayette and Westmoreland counties plus adjoining counties
  • · Hall previously served as chief lending officer and market president for the Greater Harrisburg market
  • · Steinour previously served as chief administrative officer before becoming COO
  • · Petito-Bentley previously served as deputy director of human resources and performance coach
  • · Mid Penn Bank was founded in 1868 and is headquartered in Millersburg, Pennsylvania
  • · All new appointees report directly to Ritrievi or Micklewright per the new reporting structure
TE Connectivity plc 8-K neutral materiality 3/10

02-11-2026

TE Connectivity announced that EVP and General Counsel John S. Jenkins, Jr. notified the company on October 28, 2026 of his retirement effective March 31, 2027. He will step down from his current role when successor Jennifer A. Johnson joins as EVP and Chief Legal Officer, anticipated November 9, 2026, and will remain employed as an executive legal advisor until retirement at the same annual salary with prorated AIP eligibility. No financial terms or monetary amounts were disclosed.

  • · Jenkins' retirement effective date is March 31, 2027
  • · Successor Jennifer A. Johnson's start date anticipated November 9, 2026
  • · Jenkins will retain the same annual salary as executive legal advisor, with AIP awards subject to proration
  • · Filing signed November 2, 2026 by Harold G. Barksdale, Vice President and Corporate Secretary
  • · Company incorporated in Ireland, Commission File Number 001-33260
CSB Bancorp, Inc. 8-K neutral materiality 4/10

02-11-2026

CSB Bancorp, Inc. (OTC ID: CSBB) disclosed in an 8-K that Senior Vice President and Chief Financial Officer Paula J. Meiler will retire effective April 30, 2027, and will continue serving as CFO through that date to support a seamless transition. The company stated the retirement is not the result of any disagreement over operations, policies, practices, or financial reporting, and the Board has launched a comprehensive search considering both internal and external candidates. No financial figures or period-over-period metrics were disclosed in the filing.

  • · Retirement effective date: April 30, 2027
  • · 8-K date of earliest event reported: October 30, 2026; filing date: November 2, 2026
  • · Company headquarters: 91 North Clay Street, P.O. Box 232, Millersburg, Ohio 44654
  • · Commission File Number 000-21714; IRS Employer Identification No. 34-1687530; incorporated in Ohio
  • · Common stock trades on OTCID under symbol CSBB
  • · Filing signed by Eddie L. Steiner, President and Chief Executive Officer
APOGEE ENTERPRISES, INC. 8-K neutral materiality 5/10

02-11-2026

Apogee Enterprises extended CEO and Executive Chair Donald A. Nolan's employment from November 1, 2026 through April 30, 2027, as his prior term was set to expire October 31, 2026, while the Board continues its search for a permanent CEO. During the extended term Nolan keeps an annualized base salary of $925,000 and is eligible for a transition bonus of up to $250,000, a one-time $25,000 cash payment for travel and lodging, and monthly time-based RSU grants at an annualized target value of $1,750,000 ($145,834 per monthly grant). The arrangement provides leadership continuity, but the CEO role remains in transition with no permanent successor named.

  • · Extended Term runs November 1, 2026 through April 30, 2027; prior term expired October 31, 2026
  • · Each monthly RSU award vests on the first anniversary of its grant date, subject to vesting conditions
  • · Upon the permanent CEO's start, Nolan ceases as CEO but remains an employee and Executive Chair through the remainder of the Extended Term
  • · Previously granted RSUs remain eligible to vest subject to continued-service conditions
  • · Terms of Nolan's October 31, 2025 offer letter remain in effect except as modified by the Extension Letter (Exhibit 10.1)
  • · Compensation Committee approved terms on October 29, 2026 and the Board subsequently approved the extension

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 39 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Corporate Board Director Changes SEC Filings

🇺🇸 More from United States

View all →